Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience.

Gisondi, Paolo; Piaserico, Stefano; Naldi, Luigi; Dapavo, Paolo; Conti, Andrea; Malagoli, Piergiorgio; Marzano, Angelo Valerio; Bardazzi, Federico; Gasperini, Massimo; Cazzaniga, Simone; Costanzo, Antonio (2021). Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience. Journal of allergy and clinical immunology, 147(2), 558-560.e1. Elsevier 10.1016/j.jaci.2020.10.032

[img] Text
main_2.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (203kB) | Request a copy

INTRODUCTION

Whether biologic therapies enhance the risk of coronavirus 2019 (COVID-19) or affect the disease outcome in patients with chronic plaque psoriasis remains to be ascertained.

OBJECTIVE

We sought to investigate the incidence of hospitalization and death for COVID-19 in a large sample of patients with plaque psoriasis receiving biologic therapies compared with the general population.

METHODS

This is a retrospective multicenter cohort study including patients with chronic plaque psoriasis (n = 6501) being treated with biologic therapy and regularly followed up at the divisions of dermatology of several main hospitals in the Northern Italian cities of Verona, Padua, Vicenza, Modena, Bologna, Piacenza, Turin, and Milan. Incidence rates of hospitalization and death per 10,000 person-months with exact mid-p 95% CIs and standardized incidence ratios were estimated in the patients with psoriasis and compared with those in the general population in the same geographic areas.

RESULTS

The incidence rate of hospitalization for COVID-19 was 11.7 (95% CI, 7.2-18.1) per 10,000 person-months in patients with psoriasis and 14.4 (95% CI, 14.3-14.5) in the general population; the incidence rate of death from COVID-19 was 1.3 (95% CI, 0.2-4.3) and 4.7 (95% CI, 4.6-4.7) in patients with psoriasis and the general population, respectively. The standardized incidence ratio of hospitalization and death in patients with psoriasis compared with those in the general population was 0.94 (95% CI, 0.57-1.45; P = .82) and 0.42 (95% CI, 0.07-1.38; P = .19), respectively.

CONCLUSIONS

Our data did not show any adverse impact of biologics on COVID-19 outcome in patients with psoriasis. We would not advise biologic discontinuation in patients on treatment since more than 6 months and not infected with severe acute respiratory syndrome coronavirus 2 to prevent hospitalization and death from COVID-19.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology

UniBE Contributor:

Cazzaniga, Simone

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1097-6825

Publisher:

Elsevier

Language:

English

Submitter:

Sandra Nyffenegger

Date Deposited:

31 Dec 2020 09:16

Last Modified:

10 Feb 2021 01:34

Publisher DOI:

10.1016/j.jaci.2020.10.032

PubMed ID:

33160968

Uncontrolled Keywords:

COVID-19 Psoriasis biologics interstitial pneumonia

BORIS DOI:

10.48350/150451

URI:

https://boris.unibe.ch/id/eprint/150451

Actions (login required)

Edit item Edit item
Provide Feedback